The Cutting Edge of Medical Technology Content, Community & Collaboration
Little Known Funding Opportunities (Up to $15 million/year) ... Embedded in U.S. Health Reform Bill
Colleagues,
As reported in GenomeWeb & various sources ...
... Tucked within the Health Reform bill are at least two lesser-known provisions that may affect biomedical researchers and teaching hospitals ...
... The bill calls for the initiation of a new competitive grant program at the National Institutes of Health (NIH), the Cures Acceleration Network (CAN). It will authorize as much as US$500 million annually for speeding the translation of basic discoveries into treatments, through individual awards of up to $15 million per year...
... Reportedly, CAN will be established within the Office of the Director of NIH. It will be overseen by a Board of 24 diverse members from several fields, including research, FDA, venture capital,
and patient advocacy. In addition, CAN will work with the FDA to coordinate approval requirements with the goal of expediting the development and approval of products ...
... As reported by MedTech-IQ "Patient-Centered Outcomes Research Institute in U.S. Health Reform ...", the bill also contains language outlining the creation of a new, independent, non-profit institute for comparative effectiveness research — evidence-based studies that compare the value of medical treatments ...
As reported in GenomeWeb & various sources ...
... Tucked within the Health Reform bill are at least two lesser-known provisions that may affect biomedical researchers and teaching hospitals ...
... The bill calls for the initiation of a new competitive grant program at the National Institutes of Health (NIH), the Cures Acceleration Network (CAN). It will authorize as much as US$500 million annually for speeding the translation of basic discoveries into treatments, through individual awards of up to $15 million per year...
... Reportedly, CAN will be established within the Office of the Director of NIH. It will be overseen by a Board of 24 diverse members from several fields, including research, FDA, venture capital,
and patient advocacy. In addition, CAN will work with the FDA to coordinate approval requirements with the goal of expediting the development and approval of products ...
... As reported by MedTech-IQ "Patient-Centered Outcomes Research Institute in U.S. Health Reform ...", the bill also contains language outlining the creation of a new, independent, non-profit institute for comparative effectiveness research — evidence-based studies that compare the value of medical treatments ...
... On the biotechnology side, we also reported earlier in MedTech-IQ, "U.S. Healthcare Reform ... Biotechnology, Politics & Healthcare", that companies producing biologics also benefit from the bill. New regulation would guarantee 12 years of market exclusivity for makers of brand-name biologics before biosimilars can be produced...
Read on at: http://www.genomeweb.com//node/936777?hq_e=el&hq_m=661846&h...
Views: 7
MedTechIQ VideoLibrary
Upcoming Events
© 2024 Created by CC-Conrad Clyburn-MedForeSight.
Powered by
